Kedrion SpA secured European orphan drug designation from the EMA for its investigational plasma-derived treatment for congenital aceruloplasminemia. The designation advances Kedrion’s program toward clinical development in Europe and provides regulatory incentives for a rare, genetically driven iron‑metabolism disorder. Company statements indicated the move will streamline Kedrion’s path to first-in-patient studies and potential market exclusivity under EU orphan rules.